Business Wire

Tavneos ® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)

Share

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England’s National Institute for Health and Care Excellence (NICE) has recommended Tavneos® in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), two main forms of AAV. The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005538/en/

“ANCA-associated vasculitis is a rare, systemic disease which can be rapidly fatal if not appropriately & promptly treated. The variable nature of the disease and its course along with challenging side-effects of current treatment options can severely affect subsequent quality of life for patients,” said John Mills, Vice-Chair of Vasculitis UK. “We very much welcome NICE’s decision, which means that eligible patients and clinicians have another choice of treatment for this debilitating condition.”

“NICE’s decision represents a major advancement for the treatment of GPA/MPA in the UK,” said Prof. David Jayne, Professor of Clinical Autoimmunity, University of Cambridge. “Patients will now have access to a new therapy option that could help them optimize their treatment outcomes.”

“We are delighted about this recommendation for patients in England, Wales and Northern Ireland living with GPA/MPA”, said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “It means that an underserved patient population will have access to a first in class treatment aiming to meet major unmet medical needs. We look forward to continue working with the National Health Service to ensure access to this important medicine for patients across the UK as quickly as possible.”

MHRA approval and the NICE recommendation were based on findings from a comprehensive development program, culminating in the results from the pivotal phase-III trial (ADVOCATE) in 331 patients with ANCA-associated vasculitis (GPA/MPA) in 20 countries. This randomized, controlled trial assigned patients to either oral Tavneos® (30mg twice daily) or oral prednisolone on a tapering schedule. All patients received induction treatment with cyclophosphamide or rituximab. The study met its primary endpoints of disease remission at week 26, defined as Birmingham Vasculitis Activity Score (BVAS) of 0 at week 26 and not taking glucocorticoids for treatment of ANCA-associated vasculitis in the previous 4 weeks, and sustained remission at both weeks 26 and 52 defined as a BVAS of 0 and not taking glucocorticoids for treatment of ANCA-associated vasculitis within 4 weeks prior to week 52. Compared to a prednisolone-based regimen, the Tavneos®-based regimen demonstrated non-inferiority in terms of remission at week 26, and superiority in terms of sustained remission at week 52. Serious adverse events (excluding worsening vasculitis) occurred in 37.3% of patients receiving Tavneos® and in 39% of those receiving prednisolone.

About CSL Vifor

CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care). The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com

About GPA and MPA

GPA and MPA are the two main forms of ANCA-associated vasculitis which is a systemic disease in which inappropriate activation of the complement pathway further activates neutrophils, leading to inflammation and destruction of small blood vessels. This results in organ damage and failure, with the kidney and lung as major targets, and may be fatal if not treated.

Treatment of GPA/MPA consists of courses of potent immuno-suppressants, in combination with high-dose glucocorticoids (steroids) for prolonged periods of time. However, the unmet medical need remains high as these patients face significant risk of complications, both from their disease and adverse effects from medications, including from long-term use of glucocorticoids. Treatment goals are to achieve sustainable remission to reduce vascular damage and preserve organ function while minimizing the side effects of current treatments.

About Tavneos® (avacopan)

Tavneos® (avacopan) is an orally administered small molecule that is a selective inhibitor of the complement C5a receptor C5aR1. By blocking this receptor (C5aR1) for the pro-inflammatory complement system fragment, C5a on inflammatory cells such as neutrophils, Tavneos® reduces the ability of those cells to do damage in response to C5a activation. Moreover, Tavneos® selective inhibition of only the C5aR1 is expected to leave the formation of the beneficial C5b-9 complex intact.

Tavneos® was developed by ChemoCentryx, Inc., who is also developing Tavneos® for the treatment of patients with C3 Glomerulopathy (C3G) and hidradenitis suppurativa (HS). The U.S. Food and Drug Administration has granted Tavneos® orphan-drug designation for ANCA-associated vasculitis, C3G and atypical hemolytic uremic syndrome. The European Commission has granted orphan medicinal product designation for Tavneos® for the treatment of two forms of ANCA-associated vasculitis: MPA and GPA (formerly known as Wegener's granulomatosis), as well as for C3G.

VFMCRP has a licensing agreement with ChemoCentryx, Inc., to commercialize Tavneos® outside the US.

# # #

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Thomas Hutter
Mobile: +41 79 957 96 73
Email: media@viforpharma.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ALL4PACK Emballage Paris – 21 to 24 November 2022: the leading international trade fair for all sustainable packaging and intralogistics solutions26.9.2022 10:00:00 CEST | Press release

The benchmark event at the end of the year (21-24 November 2022 - Paris Nord Villepinte, France), ALL4PACK Emballage Paris is the leading international trade fair for all sustainable packaging and intralogistics solutions, covering the whole production line, including machines. ALL4PACK is a source of inspiration, offering support to all industry stakeholders who are faced with ongoing and future challenges. Against this backdrop, the fair stands out by decoding market developments and regulations, and by showcasing the latest innovations. A new approach approved by exhibitors ALL4PACK Emballage Paris offers a complete range of packaging and machinery solutions for all types of industry. To date, 1,300 exhibitors are expected, of which about 50% are international exhibiters. In fact, 96% of the exhibition space has already been booked. Various leading companies such as ATLANTA STRETCH, AUER, BFR SYSTEMS, DOMINO, FILPACK, FRANPACK, FROMM, G.MONDINI, GETRA, GOGLIO, ISHIDA, KRONES, MARCHE

Adams Street Hires James Charalambides and Launches European Private Credit Strategy26.9.2022 10:00:00 CEST | Press release

Adams Street Partners, LLC, a private markets investment firm with $50 billion in assets under management, announced the launch of its Private Credit platform in Europe with the appointment of James Charalambides as Partner & Head of the European Private Credit team. Mr. Charalambides will be responsible for leading and managing the firm’s private credit-related efforts in Europe and supporting all aspects of the decision-making process – including sourcing, structuring, reviewing, and negotiating deal opportunities in this space. Mr. Charalambides will report to Bill Sacher, Partner & Head of Private Credit at Adams Street. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005177/en/ Adams Street Partners has announced the launch of its Private Credit platform in Europe with the appointment of James Charalambides as Partner & Head of the European Private Credit team. (Photo: Business Wire) Since launching its inaugural p

Guillaume Jesel Promoted to President, Global Brands, TOM FORD BEAUTY, BALMAIN BEAUTY and Luxury Business Development26.9.2022 09:00:00 CEST | Press release

Today, The Estée Lauder Companies (NYSE: EL) (“ELC”) announced that Guillaume Jesel has been promoted to President, Global Brands, TOM FORD BEAUTY, BALMAIN BEAUTY and Luxury Business Development, effective immediately. Guillaume will report to Jane Hertzmark Hudis, Executive Group President and also to Tracey T. Travis, Executive Vice President and Chief Financial Officer in her role of overseeing the company’s mergers and acquisitions strategy, for Guillaume’s Luxury Business Development responsibilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005235/en/ Guillaume Jesel has been promoted to President, Global Brands, TOM FORD BEAUTY, BALMAIN BEAUTY and Luxury Business Development (Photo: Business Wire) In this new position, Guillaume will continue to oversee TOM FORD BEAUTY and also be responsible for the overall strategic direction, global development, management and growth of BALMAIN BEAUTY. Guillaume will wo

Alipay+ Partners with Leading Asian E-Wallets to Promote Cashless Travel in South Korea26.9.2022 08:45:00 CEST | Press release

Leading mobile payment providers across Asia announced today an integration of Alipay+ cross-border digital payment solutions in South Korea in an effort to jointly promote cashless travel in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220925005072/en/ Users of leading Asian e-wallets including AlipayHK, GCash (the Philippines), Touch ‘n Go (Malaysia), and TrueMoney (Thailand) are able to pay at over 120,000 merchants using their local mobile payment apps when traveling in South Korea. (Photo: Business Wire) Users of e-wallets including AlipayHK, GCash (the Philippines), Touch ‘n Go eWallet (Malaysia), and TrueMoney (Thailand) are able to pay at over 120,000 merchants using their local mobile payment apps when traveling in South Korea. The collaboration marks the first time for leading mobile payment providers from Southeast Asia and Hong Kong to extend the availability of their services in South Korea throug

The Estée Lauder Companies and BALMAIN are Partnering to Launch BALMAIN BEAUTY26.9.2022 08:00:00 CEST | Press release

The Estée Lauder Companies Inc. (NYSE: EL) (“ELC”) and BALMAIN have entered into a license agreement to collaboratively develop, produce, and distribute an innovative line of beauty products that will speak to luxury consumers around the world: BALMAIN BEAUTY. The collaboration is expected to launch in fall 2024, with the goal to transform the luxury and couture beauty world through exceptional design, singular craftsmanship, and an unyielding commitment to innovation. In 1945, when founder Pierre Balmain boldly introduced his audacious, fresh, and feminine “New French Style,” Balmain helped post-war Paris begin to regain its title as the fashion world’s capital. Today’s BALMAIN, under the visionary leadership of Creative Director Olivier Rousteing since 2011, builds upon Pierre Balmain’s legacy, with the house’s rich archives providing key inspirations and the legendary savoir-faire of Balmain’s atelier ensuring the success of Rousteing’s distinctive “Renewed French Style.” While reve

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom